title: Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
abstract: OBJECTIVE
  The efficacy of a cetuximab-based regimen used to treat metastatic colorectal cancer (mCRC) could be influenced by VEGFA polymorphisms.
  
  
  METHODS
  We studied the effects of five polymorphisms in the VEGFA gene (-2549D/I, -1154G/A, -460T/C, +405G/C and +936C/T) on the outcome of 98 mCRC patients treated with FOLFIRI plus cetuximab.
  
  
  RESULTS
  Patients homozygous for the -2549D, -1154G and -460T alleles did exhibit higher response rates to treatment and longer progression-free survival compared with others. In addition, the DGTGC and IGCGC haplotypes were significantly associated with a lower risk of disease progression.
  
  
  CONCLUSIONS
  These findings suggest that VEGFA genetic variations might influence response/resistance of FOLFIRI plus cetuximab treatment in mCRC patients.
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service d'Hématologie-Hémostase, Tours, France.
authors.forename: Jérôme
authors.initials: J
authors.lastname: Rollin
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service d'Hématologie-Hémostase, Tours, France.|CHRU de Tours, service d'Hépato-Gastroenterologie, Tours, France.
authors.forename: Audrey
authors.initials: A
authors.lastname: Payancé
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service d'Immunologie, Tours, France.
authors.forename: Valérie
authors.initials: V
authors.lastname: Gouilleux-Gruart
authors.affiliation: INSERM U892 & service d'Oncopharmacologie et Pharmacogénétique, CRCNA, Angers, France.
authors.forename: Michelle
authors.initials: M
authors.lastname: Boisdron-Celle
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Azzopardi
authors.affiliation: INSERM U892 & service d'Oncopharmacologie et Pharmacogénétique, CRCNA, Angers, France.
authors.forename: Alain
authors.initials: A
authors.lastname: Morel
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service d'Hématologie-Hémostase, Tours, France.
authors.forename: Yves
authors.initials: Y
authors.lastname: Gruel
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service de Pharmacologie-Toxicologie, Tours, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Paintaud
authors.affiliation: INSERM U892 & service d'Oncopharmacologie et Pharmacogénétique, CRCNA, Angers, France.
authors.forename: Erick
authors.initials: E
authors.lastname: Gamelin
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service d'Immunologie, Tours, France.
authors.forename: Hervé
authors.initials: H
authors.lastname: Watier
authors.affiliation: CNRS, UMR 7292, GICC & Université Francois-Rabelais, Tours, France.|CHRU de Tours, service d'Hépato-Gastroenterologie, Tours, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Lecomte
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068818:Cetuximab / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D009362:Neoplasm Metastasis; D011110:Polymorphism, Genetic; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics*
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin
keywords: SNPs; VEGFA; biomarkers; cetuximab; colorectal cancer